What's on the Horizon: The Lyme Vaccine

After going decades without a real Lyme vaccine for people, there's finally something worth paying attention to.

Back in March 2026, Pfizer and Valneva put out their Phase 3 results for VLA15, a Lyme vaccine they've been working on. The trial, they call it VALOR, showed it stopped 73.2% of confirmed Lyme cases starting 28 days after the last shot in the second season of testing.

Let me put that in plain terms. 73% doesn't mean 27 out of 100 vaccinated people get Lyme. It means the group that got the vaccine had 73% fewer confirmed cases than the group that got a placebo. For folks who actually spend time in tick country, that's a real difference.

How It Works

The vaccine goes after a protein called OspA that sits on the surface of the Lyme bacteria while it's still inside the tick, before it ever gets into you. So when a vaccinated person gets bitten, the antibodies in their blood actually go into the tick during the bite and kill the bacteria right there, before it can make the jump over to the person. Kind of a strange way for a vaccine to work, fighting the infection inside the tick instead of inside you, but that's the idea.

In the trial, people got four shots: at the start, then at two months, then somewhere between five and nine months, then a booster a year after the third shot. Pfizer and Valneva say they're moving toward submitting this for approval. Right now there's no approved Lyme vaccine for people in this country at all. There used to be one, LYMErix, but it got pulled back in 2002 because not enough people were buying it, even though it worked fine and was safe.

There's a separate safety trial running now for kids 5 to 17. That matters a lot, kids are some of the most likely to get Lyme just because of how much time they spend outside and how easy it is to miss a tiny tick on them.